Effect of nintedanib on cough and health related quality of life in patients with idiopathic pulmonary fibrosis

Introduction and Aim: Patients with Idiopathic Pulmonary Fibrosis (IPF) experience progressive dyspnea, fatigue and cough, with severe impact on their health related quality of life (HRQOL). Nintedanib has shown to decrease disease progression, but did not significantly affect HRQOL measured with a non-disease specific questionnaire. We investigate the effect of Nintedanib on cough and HRQOL, in patients with IPF, measured with disease and symptom specific questionnaires. Methods: Consecutive outpatients, starting on Nintedanib, were asked to participate. Before and after 1 and 3 months of treatment patients completed the King9s Brief Interstitial Lung Disease health status questionnaire (K-BILD), Leicester Cough Questionnaire (LCQ), Cough Visual Analogue Scale (VAS) and Urge to cough VAS. Results: We report the preliminary results of the first 15 patients (10 male) included. Mean age was 69 (47-79), baseline mean FVC and TLCOc % predicted were respectively 76 (54-100) and 45 (19-64). Questionnaire scores at month 1 and 3 did not significantly differ from baseline (Table 1). Conclusion: These preliminary results show no effect of Nintedanib on cough and HRQOL, measured with disease and symptom specific questionnaires in patients with IPF.